These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 17486946)

  • 1. Assessment of the impact of weekly versus monthly erythropoiesis stimulating protein therapy on patients with CKD and their families.
    Globe D; Glidden D; Hertel J; Thomas J; Ackerman M; Chidolue F; Blanco B; Borden A; Goss TF; Xu X; Kewalramani R
    Nephrol Nurs J; 2007; 34(2):151-61. PubMed ID: 17486946
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The continuous erythropoietin receptor activator (C.E.R.A.) corrects anemia at extended administration intervals in patients with chronic kidney disease not on dialysis: results of a phase II study.
    Provenzano R; Besarab A; Macdougall IC; Ellison DH; Maxwell AP; Sulowicz W; Klinger M; Rutkowski B; Correa-Rotter R; Dougherty FC;
    Clin Nephrol; 2007 May; 67(5):306-17. PubMed ID: 17542340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of erythropoiesis-stimulating agents on healthcare utilization, costs, and outcomes in chronic kidney disease.
    Maddux FW; Shetty S; del Aguila MA; Nelson MA; Murray BM
    Ann Pharmacother; 2007 Nov; 41(11):1761-9. PubMed ID: 17895328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Costs of managing anemia with erythropoiesis-stimulating agents during hemodialysis: a time and motion study.
    Schiller B; Doss S; DE Cock E; Del Aguila MA; Nissenson AR
    Hemodial Int; 2008 Oct; 12(4):441-9. PubMed ID: 19090867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and pharmacodynamics of intravenous and subcutaneous continuous erythropoietin receptor activator (C.E.R.A.) in patients with chronic kidney disease.
    Macdougall IC; Robson R; Opatrna S; Liogier X; Pannier A; Jordan P; Dougherty FC; Reigner B
    Clin J Am Soc Nephrol; 2006 Nov; 1(6):1211-5. PubMed ID: 17699350
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly.
    Sulowicz W; Locatelli F; Ryckelynck JP; Balla J; Csiky B; Harris K; Ehrhard P; Beyer U;
    Clin J Am Soc Nephrol; 2007 Jul; 2(4):637-46. PubMed ID: 17699476
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Treatment of renal anemia with intravenous erythropoietin in patients in the program of continuous ambulatory peritoneal dialysis].
    Zelichowski G; Lubas A; Sienkiewicz M; Janusz E; Wańkowicz Z
    Pol Merkur Lekarski; 2008 Apr; 24(142):312-5. PubMed ID: 18634362
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel erythropoiesis-stimulating agents: a new era in anemia management.
    Macdougall IC
    Clin J Am Soc Nephrol; 2008 Jan; 3(1):200-7. PubMed ID: 18077782
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease.
    Besarab A; Salifu MO; Lunde NM; Bansal V; Fishbane S; Dougherty FC; Beyer U;
    Clin Ther; 2007 Apr; 29(4):626-39. PubMed ID: 17617286
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Control-relevant erythropoiesis modeling in end-stage renal disease.
    Chait Y; Horowitz J; Nichols B; Shrestha RP; Hollot CV; Germain MJ
    IEEE Trans Biomed Eng; 2014 Mar; 61(3):658-64. PubMed ID: 24235247
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exploring dosing frequency and administration routes in the treatment of anaemia in CKD patients.
    Portolés J; Krisper P; Choukroun G; de Francisco AL
    Nephrol Dial Transplant; 2005 Sep; 20 Suppl 8():viii13-17. PubMed ID: 16079324
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of time and practice resources required to provide weekly or monthly erythropoiesis-stimulating protein therapy to chronic kidney disease patients in the physician office setting.
    Bernardo M; Crawford P; Hertel J; Sholer C; Xu X; Goss T; Kewalramani R; Globe D
    J Manag Care Pharm; 2006; 12(9):714-25. PubMed ID: 17249904
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison between once-weekly and twice- or thrice-weekly subcutaneous injection of epoetin alfa: results from a randomized controlled multicentre study.
    Lee YK; Kim SG; Seo JW; Oh JE; Yoon JW; Koo JR; Kim HJ; Noh JW
    Nephrol Dial Transplant; 2008 Oct; 23(10):3240-6. PubMed ID: 18469158
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biocompatibility and permeability of dialyzer membranes do not affect anemia, erythropoietin dosage or mortality in japanese patients on chronic non-reuse hemodialysis: a prospective cohort study from the J-DOPPS II study.
    Yokoyama H; Kawaguchi T; Wada T; Takahashi Y; Higashi T; Yamazaki S; Fukuhara S; Akiba T; Akizawa T; Asano Y; Kurokawa K; Saito A;
    Nephron Clin Pract; 2008; 109(2):c100-8. PubMed ID: 18596379
    [TBL] [Abstract][Full Text] [Related]  

  • 15. From anemia trials to clinical practice: understanding the risks and benefits when setting goals for therapy.
    Coyne DW
    Semin Dial; 2008; 21(3):212-6. PubMed ID: 18363603
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pure red cell aplasia induced by erythropoiesis-stimulating agents.
    Pollock C; Johnson DW; Hörl WH; Rossert J; Casadevall N; Schellekens H; Delage R; De Francisco A; Macdougall I; Thorpe R; Toffelmire E
    Clin J Am Soc Nephrol; 2008 Jan; 3(1):193-9. PubMed ID: 18178785
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renal anemia: comparing current Eastern and Western European management practice (ORAMA).
    Wiecek A; Covic A; Locatelli F; Macdougall IC;
    Ren Fail; 2008; 30(3):267-76. PubMed ID: 18350446
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simplification of an erythropoiesis model for design of anemia management protocols in end stage renal disease.
    Nichols B; Shrestha RP; Horowitz J; Hollot CV; Germain MJ; Gaweda AE; Chait Y
    Annu Int Conf IEEE Eng Med Biol Soc; 2011; 2011():83-6. PubMed ID: 22254256
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ORAMA: a study to investigate EBPG impact on renal anaemia - design and baseline data.
    Locatelli F; Covic A; Macdougall IC; Wiecek A;
    J Nephrol; 2008; 21(4):592-603. PubMed ID: 18651551
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of parathyroidectomy on anemia and erythropoietin dosing in end-stage renal disease patients with hyperparathyroidism.
    Trunzo JA; McHenry CR; Schulak JA; Wilhelm SM
    Surgery; 2008 Dec; 144(6):915-8; discussion 919. PubMed ID: 19040997
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.